This is in line with its efforts to take advantage of growth opportunities in Singapore and the wider Asia-Pacific region, said chairman and chief executive officer Todd Dollinger at a briefing on Monday.

It was part of the firm’s roadshow showcasing seven of the medical technology companies in its portfolio – the first time it has held such an event here.

The firms include Escala Medical, which has developed a non-surgical, incision-free approach to treat pelvic organ prolapse, and Elasti Med, which has made an easy-to-wear compression stocking using smart materials.

The roadshow aims to give investors a “touch and feel” of Trendlines’ portfolio, said Steve Rhodes, also a chairman and CEO of the group.

“Our main asset is the value of our portfolio companies,” he said.

“The value that we give each of these companies in our books is lower than the actual value of these companies,” he said.

“The methodology used for valuing the companies on our books is very conservative. It’s typically based on the last money invested in the company.

“We think that when people understand the potential in these companies, they’ll understand the hidden value within (our) portfolio.”

Trendlines Group was founded in 2007 by Rhodes and Dollinger, and was listed on the Singapore bourse last November.

It makes early-stage investments in the medical and agritech fields, and now manages a portfolio of almost 50 companies.

The company is looking to partner with both industry and government agencies here to support the activities of its new incubator, called Trendlines Medical Singapore.

The incubator will focus on “specific areas of interest for the partners we’re working with” as well as “producing and inventing products that have a special interest for Asia-Pacific”, Dollinger said.

Eric Loh, formerly senior vice president at Singapore-listed stent maker Biosensors, has been appointed CEO of Trendlines Medical Singapore.